Comparative Pharmacology
Head-to-head clinical analysis: NEOSPORIN versus VUSION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOSPORIN versus VUSION.
NEOSPORIN vs VUSION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neosporin is a combination of three antibiotics: neomycin (aminoglycoside) inhibits bacterial protein synthesis by binding to 30S ribosomal subunit; polymyxin B (polymyxin) disrupts bacterial cell membrane integrity; bacitracin (polypeptide) inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
Antifungal; inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell membrane synthesis.
Apply a thin layer topically to the affected area 1-3 times daily. May be covered with a sterile bandage.
Apply a thin layer to the affected area twice daily (morning and evening) for 7 days. Topical use only.
None Documented
None Documented
Variable based on severity of renal impairment. Normal renal function: 2-3 hours for neomycin (main component); polymyxin B: 4-6 hours. In anuria: half-life extends to 72-96 hours for neomycin.
Terminal elimination half-life is approximately 36 hours, reflecting prolonged exposure in stratum corneum and hair follicles; systemic half-life is negligible due to minimal percutaneous absorption.
Renal excretion accounts for >90% of elimination; primarily glomerular filtration with minimal tubular secretion. Small biliary/fecal elimination (<5%).
Primarily eliminated via biliary/fecal route; minimal renal excretion (<5% unchanged). Approximately 80% of the absorbed dose appears in feces as unchanged drug and metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic